Event-Free Survival after 68Ga-PSMA-11 PET/CT in recurrent Hormone-Sensitive Prostate Cancer (HSPC) patients eligible for Salvage Therapy.
Francesco Ceci(University of Turin), Désirèe Deandreis, Paolo Gontero(Fondazione Ricerca Molinette), Giuseppe Carlo Iorio(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Umberto Ricardi(University of Turin), Guido Rovera(Università Cattolica del Sacro Cuore), Marco Oderda(University of Turin), Séréna Grimaldi(Université Paris-Saclay), Roberto Passera(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Sara Dall’Armellina(University of Turin), Marilena Bellò, Valeria Chiofalo(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Alessia Guarneri(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Virginia Liberini(University of Turin)
Cited by 2
Related Papers
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
|The Lancet Oncology|2020|1.1k
Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
|New England Journal of Medicine|2013|825
Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document
|Radiotherapy and Oncology|2020|646